One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Patient Experiences with Home Dialysis
James Myers
doi : 10.2215/CJN.01570221
CJASN April 2021, 16 (4) 497-498
Digital Solutions to Improve Medication Safety in CKD
Lee-Ann Wagner and Jeffrey C. Fink
doi : 10.2215/CJN.01680221
CJASN April 2021, 16 (4) 499-501
A New View of Iron Management in Heart Failure
Nupur N. Uppal and Steven Fishbane
doi : 10.2215/CJN.01850221
CJASN April 2021, 16 (4) 502-504
The Promise and Challenge of Aerobic Exercise in People Undergoing Long-Term Hemodialysis
Kirsten L. Johansen
doi : 10.2215/CJN.01960221
CJASN April 2021, 16 (4) 505-507
Measuring Patient Experience with Home Dialysis in the United States
Brian M. Brady and Manjula Kurella Tamura
doi : 10.2215/CJN.01990221
CJASN April 2021, 16 (4) 508-510
Therapeutic Options to Improve Cardiovascular Outcomes with Long-Term Hemodialysis
Maya N. Clark-Cutaia and Raymond R. Townsend
doi : 10.2215/CJN.02010221
CJASN April 2021, 16 (4) 511-513
Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients
Alexandre Karras, Marine Livrozet, Hélène Lazareth, Nicolas Benichou, Jean-Sébastien Hulot, Antoine Fayol, Sophie Chauvet, Anne-Sophie Jannot, Marie-Aude Penet, Jean-Luc Diehl, Anne Godier, Olivier Sanchez, Tristan Mirault, Eric Thervet and Nicolas Pallet
doi : 10.2215/CJN.09130620
CJASN April 2021, 16 (4) 514-521
Background and objectives Kidney involvement is frequent among patients with coronavirus disease 2019 (COVID-19), and occurrence of AKI is associated with higher mortality in this population. The objective of this study was to describe occurrence and significance of proteinuria in this setting.
Heart Failure Hospitalization Risk associated with Iron Status in Veterans with CKD
Monique E. Cho, Jared L. Hansen, Brian C. Sauer, Alfred K. Cheung, Adhish Agarwal and Tom Greene
doi : 10.2215/CJN.15360920
CJASN April 2021, 16 (4) 522-531
Background and objectives CKD is an independent risk factor for heart failure. Iron dysmetabolism potentially contributes to heart failure, but this relationship has not been well characterized in CKD.
Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients
Stephanie W. Ong, Sarbjit V. Jassal, Eveline C. Porter, Kyoyoon K. Min, Akib Uddin, Joseph A. Cafazzo, Valeria E. Rac, George Tomlinson and Alexander G. Logan
doi : 10.2215/CJN.15020920
CJASN April 2021, 16 (4) 532-542
Background and objectives Patients with CKD are at risk for adverse drug reactions, but effective community-based preventive programs remain elusive. In this study, we compared the effectiveness of two digital applications designed to improve outpatient medication safety.
Identification of Patients with CKD in Medical Databases
S?ren Viborg Vestergaard, Christian Fynbo Christiansen, Reimar Wernich Thomsen, Henrik Birn and Uffe Heide-J?rgensen
doi : 10.2215/CJN.15691020
CJASN April 2021, 16 (4) 543-551
Background and objectives Despite CKD consensus definitions, epidemiologic studies use multiple different algorithms to identify CKD. We aimed to elucidate if this affects the patient characteristics and the estimated prevalence and prognosis of CKD by applying six different algorithms to identify CKD in population-based medical databases and compare the cohorts.
Provider Perception of Frailty Is Associated with Dialysis Decision Making in Patients with Advanced CKD
Ranveer S. Brar, Reid H. Whitlock, Paul V.J. Komenda, Claudio Rigatto, Bhanu Prasad, Clara Bohm and Navdeep Tangri
doi : 10.2215/CJN.12480720
CJASN April 2021, 16 (4) 552-559
Background and objectives Frailty is common in patients with CKD. Little is known about the prevalence of frailty and its effect on prognosis and decisions surrounding dialysis modalities in patients with advanced CKD (eGFR<30 ml/min per 1.73 m2). Our objective was to determine the agreement between different frailty measures and physical function and their association with dialysis modality choice (home based versus in-center) and all-cause mortality in patients with advanced CKD.
Effect of Aerobic Exercise on Dialysis-Related Symptoms in Individuals Undergoing Maintenance Hemodialysis
Nicholas Hargrove, Nada El Tobgy, Olivia Zhou, Mark Pinder, Brittany Plant, Nicole Askin, Laura Bieber, David Collister, Reid Whitlock, Navdeep Tangri and Clara Bohm
doi : 10.2215/CJN.15080920
CJASN April 2021, 16 (4) 560-574
Background Hemodialysis is associated with a high symptom burden that impairs health-related quality of life and functional status. Effective symptom management is a priority for individuals receiving hemodialysis. Aerobic exercise may be an effective, nonpharmacologic treatment for specific hemodialysis-related symptoms. This systematic review investigated the effect of aerobic exercise on hemodialysis-related symptoms in adults with kidney failure undergoing maintenance hemodialysis.
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis
Piero Ruggenenti, Manuel Alfredo Podestà, Matias Trillini, Annalisa Perna, Tobia Peracchi, Nadia Rubis, Davide Villa, Davide Martinetti, Monica Cortinovis, Patrizia Ondei, Carmela Giuseppina Condemi, Carlo Maria Guastoni, Agnese Meterangelis, Antonio Granata, Emanuele Mambelli, Sonia Pasquali, Simonetta Genovesi, Federico Pieruzzi, Silvio Volmer Bertoli, Goffredo Del Rosso, Maurizio Garozzo, Angelo Rigotti, Claudio Pozzi, Salvatore David, Giuseppe Daidone, Giulio Mingardi, Giovanni Mosconi, Andrea Galfré, Giorgio Romei Longhena, Alfonso Pacitti, Antonello Pani, Jorge Hidalgo Godoy, Hans-Joachim Anders, Giuseppe Remuzzi and on behalf of the ARCADIA Study Organization
doi : 10.2215/CJN.12940820
CJASN April 2021, 16 (4) 575-587
Background and objectives Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis.
Development and Content Validity of a Patient-Reported Experience Measure for Home Dialysis
Matthew B. Rivara, Todd Edwards, Donald Patrick, Lisa Anderson, Jonathan Himmelfarb and Rajnish Mehrotra
doi : 10.2215/CJN.15570920
CJASN April 2021, 16 (4) 588-598
Background and objectives The population of patients with kidney failure in the United States using home dialysis modalities is growing rapidly. Unlike for in-center hemodialysis, there is no patient-reported experience measure for assessment of patient experience of care for peritoneal dialysis or home hemodialysis. We sought to develop and establish content validity of a patient-reported experience measure for patients undergoing home dialysis using a mixed methods multiple stakeholder approach.
Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism
Tetsuo Shoji, Shinya Nakatani, Daijiro Kabata, Katsuhito Mori, Ayumi Shintani, Hisako Yoshida, Kanae Takahashi, Keiko Ota, Hisako Fujii, Shinichiro Ueda, Shinichi Nishi, Tatsuya Nakatani, Minoru Yoshiyama, Kiyoshi Goto, Takayoshi Hamada, Masahito Imanishi, Eiji Ishimura, Sosuke Kagitani, Yoshikazu Kato, Yasuro Kumeda, Kiyoshi Maekawa, Takayasu Matsumura, Harumi Nagayama, Yasue Obi, Yoshiteru Ohno, Yoshinori Sai, Mayumi Sakurai, Satoshi Sasaki, Kaori Shidara, Shigeichi Shoji, Yoshihiro Tsujimoto, Kenjiro Yamakawa, Hideaki Yasuda, Shozo Yodoi, Masaaki Inaba and Masanori Emoto
doi : 10.2215/CJN.16601020
CJASN April 2021, 16 (4) 599-612
Background and objectives Vitamin D receptor activators and calcimimetics (calcium-sensing receptor agonists) are two major options for medical treatment of secondary hyperparathyroidism. A higher serum calcification propensity (a shorter T50 value) is a novel surrogate marker of calcification stress and mortality in patients with CKD. We tested a hypothesis that a calcimimetic agent etelcalcetide is more effective in increasing T50 value than a vitamin D receptor activator maxacalcitol.
A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a Belgian Hemodialysis Facility
Laura Labriola, Anaïs Scohy, François Seghers, Quentin Perlot, Julien De Greef, Christine Desmet, Cécile Romain, Johann Morelle, Jean-Cyr Yombi, Benoît Kabamba, Hector Rodriguez-Villalobos and Michel Jadoul
doi : 10.2215/CJN.12490720
CJASN April 2021, 16 (4) 613-614
Nephronophthisis in Young Adults Phenocopying Thrombotic Microangiopathy and Severe Nephrosclerosis
Alice Doreille, Laure Raymond, Anne-Sophie Lebre, Charel Linster, Radoslava Saraeva Lamri, Alexandre Karras, Rateb Khayat, Pierre-Antoine Michel, David Buob, Yosu Luque, Cédric Rafat and Laurent Mesnard
doi : 10.2215/CJN.11890720
CJASN April 2021, 16 (4) 615-617
Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19
Hua Su, Cheng Wan, Zhen-Di Wang, Yong Gao, Yun-Cheng Li, Fang Tang, Hong-Yan Zhu, Li-Xia Yi and Chun Zhang
doi : 10.2215/CJN.09440620
CJASN April 2021, 16 (4) 618-619
Inherited Tubulopathies of the Kidney
Mallory L. Downie, Sergio C. Lopez Garcia, Robert Kleta and Detlef Bockenhauer
doi : 10.2215/CJN.14481119
CJASN April 2021, 16 (4) 620-630
The kidney tubules provide homeostasis by maintaining the external milieu that is critical for proper cellular function. Without homeostasis, there would be no heartbeat, no muscle movement, no thought, sensation, or emotion. The task is achieved by an orchestra of proteins, directly or indirectly involved in the tubular transport of water and solutes. Inherited tubulopathies are characterized by impaired function of one or more of these specific transport molecules. The clinical consequences can range from isolated alterations in the concentration of specific solutes in blood or urine to serious and life-threatening disorders of homeostasis. In this review, we focus on genetic aspects of the tubulopathies and how genetic investigations and kidney physiology have crossfertilized each other and facilitated the identification of these disorders and their molecular basis. In turn, clinical investigations of genetically defined patients have shaped our understanding of kidney physiology.
SGLT2 Inhibitors in Diabetic Kidney Disease
Sophia Zoungas and Ian H. de Boer
doi : 10.2215/CJN.18881220
CJASN April 2021, 16 (4) 631-633
Overview of Various Components of the Science of Patient Input
Murray Sheldon
doi : 10.2215/CJN.11760720
CJASN April 2021, 16 (4) 634-635
Integrating Patient Perspectives into Medical Device Regulatory Decision Making to Advance Innovation in Kidney Disease
Michelle E. Tarver and Carolyn Neuland
doi : 10.2215/CJN.11510720
CJASN April 2021, 16 (4) 636-638
Incorporating Patient Preferences via Bayesian Decision Analysis
Shomesh E. Chaudhuri and Andrew W. Lo
doi : 10.2215/CJN.12110720
CJASN April 2021, 16 (4) 639-641
Using Patient Preference Information to Inform Regulatory Decision Making
Jennifer E. Flythe and Melissa West
doi : 10.2215/CJN.11930720
CJASN April 2021, 16 (4) 642-644
Legitimization and Incorporation of Patient Preferences
Paul T. Conway and Richard Knight
doi : 10.2215/CJN.11780720
CJASN April 2021, 16 (4) 645-647
Risk Factors for CKD Progression
Mary Hannan, Sajid Ansari, Natalie Meza, Amanda H. Anderson, Anand Srivastava, Sushrut Waikar, Jeanne Charleston, Matthew R. Weir, Jonathan Taliercio, Edward Horwitz, Milda R. Saunders, Katherine Wolfrum, Harold I. Feldman, James P. Lash, Ana C. Ricardo and the CRIC Study Investigators
doi : 10.2215/CJN.07830520
CJASN April 2021, 16 (4) 648-659
The Chronic Renal Insufficiency Cohort (CRIC) Study is an ongoing, multicenter, longitudinal study of nearly 5500 adults with CKD in the United States. Over the past 10 years, the CRIC Study has made significant contributions to the understanding of factors associated with CKD progression. This review summarizes findings from longitudinal studies evaluating risk factors associated with CKD progression in the CRIC Study, grouped into the following six thematic categories: (1) sociodemographic and economic (sex, race/ethnicity, and nephrology care); (2) behavioral (healthy lifestyle, diet, and sleep); (3) genetic (apoL1, genome-wide association study, and renin-angiotensin-aldosterone system pathway genes); (4) cardiovascular (atrial fibrillation, hypertension, and vascular stiffness); (5) metabolic (fibroblast growth factor 23 and urinary oxalate); and (6) novel factors (AKI and biomarkers of kidney injury). Additionally, we highlight areas where future research is needed, and opportunities for interdisciplinary collaboration.
Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project
Katherine R. Tuttle, Richard Knight, Paul S. Appelbaum, Tanima Arora, Shweta Bansal, Jack Bebiak, Keith Brown, Catherine Campbell, Leslie Cooperman, Celia P. Corona-Villalobos, Ashveena Dighe, Ian H. de Boer, Daniel E. Hall, Nichole Jefferson, Stacey Jolly, Asra Kermani, Simon C. Lee, Karla Mehl, Raghavan Murugan, Glenda V. Roberts, Sylvia E. Rosas, Jonathan Himmelfarb, R. Tyler Miller and for the Kidney Precision Medicine Project
doi : 10.2215/CJN.10270620
CJASN April 2021, 16 (4) 660-668
The Kidney Precision Medicine Project (KPMP) is a multisite study designed to improve understanding of CKD attributed to diabetes or hypertension and AKI by performing protocol-driven kidney biopsies. Study participants and their kidney tissue samples undergo state-of-the-art deep phenotyping using advanced molecular, imaging, and data analytical methods. Few patients participate in research design or concepts for discovery science. A major goal of the KPMP is to include patients as equal partners to inform the research for clinically relevant benefit. The purpose of this report is to describe patient and community engagement and the value they bring to the KPMP. Patients with CKD and AKI and clinicians from the study sites are members of the Community Engagement Committee, with representation on other KPMP committees. They participate in KPMP deliberations to address scientific, clinical, logistic, analytic, ethical, and community engagement issues. The Community Engagement Committee guides KPMP research priorities from perspectives of patients and clinicians. Patients led development of essential study components, including the informed consent process, no-fault harm insurance coverage, the ethics statement, return of results plan, a “Patient Primer” for scientists and the public, and Community Advisory Boards. As members across other KPMP committees, the Community Engagement Committee assures that the science is developed and conducted in a manner relevant to study participants and the clinical community. Patients have guided the KPMP to produce research aligned with their priorities. The Community Engagement Committee partnership has set new benchmarks for patient leadership in precision medicine research.
